Cancers (Feb 2021)
Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma
- Hideki Iwamoto,
- Takashi Niizeki,
- Hiroaki Nagamatsu,
- Kazuomi Ueshima,
- Takako Nomura,
- Teiji Kuzuya,
- Kazuhiro Kasai,
- Yohei Kooka,
- Atsushi Hiraoka,
- Rie Sugimoto,
- Takehiro Yonezawa,
- Akio Ishihara,
- Akihiro Deguchi,
- Hirotaka Arai,
- Shigeo Shimose,
- Tomotake Shirono,
- Masahito Nakano,
- Shusuke Okamura,
- Yu Noda,
- Naoki Kamachi,
- Miwa Sakai,
- Hiroyuki Suzuki,
- Hajime Aino,
- Norito Matsukuma,
- Satoru Matsugaki,
- Kei Ogata,
- Yoichi Yano,
- Takato Ueno,
- Masahiko Kajiwara,
- Satoshi Itano,
- Kunitaka Fukuizumi,
- Hiroshi Kawano,
- Kazunori Noguchi,
- Masatoshi Tanaka,
- Taizo Yamaguchi,
- Ryoko Kuromatsu,
- Atsushi Kawaguchi,
- Hironori Koga,
- Takuji Torimura,
- New FP Study Group,
- Kurume Liver Cancer Study Group of Japan
Affiliations
- Hideki Iwamoto
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Takashi Niizeki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Hiroaki Nagamatsu
- Department of Gastroenterology, Juntendo University, Bunkyo-ku 113-8421, Japan
- Kazuomi Ueshima
- Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka 589-8511, Japan
- Takako Nomura
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki 761-0793, Japan
- Teiji Kuzuya
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan
- Kazuhiro Kasai
- Division of Gastroenterology, IMS Sapporo Digestive Disease Center General Hospital, Sapporo 063-0842, Japan
- Yohei Kooka
- Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate 028-3695, Japan
- Atsushi Hiraoka
- Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama 790-0024, Japan
- Rie Sugimoto
- Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka 811-1395, Japan
- Takehiro Yonezawa
- Department of Gastroenterology, Hachinohe Red Cross Hospital, Aomori 039-1104, Japan
- Akio Ishihara
- Department of Gastroenterology, Osaka National Hospital, Osaka 540-0006, Japan
- Akihiro Deguchi
- Department of Gastroenterology, Kagawa Rosai Hospital, Marugame 763-8502, Japan
- Hirotaka Arai
- Department of Gastroenterology, Maebashi Red Cross Hospital, Maebashi 371-0811, Japan
- Shigeo Shimose
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Tomotake Shirono
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Masahito Nakano
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Shusuke Okamura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Yu Noda
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Naoki Kamachi
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Miwa Sakai
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Hiroyuki Suzuki
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Hajime Aino
- Division of Gastroenterology, Department of Medicine, Social Insurance Tagawa Hospital, Tagawa 826-0023, Japan
- Norito Matsukuma
- Department of Gastroenterology, Kurume General Hospital, Kurume 830-8521, Japan
- Satoru Matsugaki
- Department of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyusyu 804-0093, Japan
- Kei Ogata
- Department of Gastroenterology, Kurume University Medical Center, Kurume 839-0863, Japan
- Yoichi Yano
- Department of Gastroenterology, Saga Central Hospital, Saga 849-8522, Japan
- Takato Ueno
- Department of Gastroenterology, Asakura Medical Association Hospital, Asakura 838-0069, Japan
- Masahiko Kajiwara
- Department of Gastroenterology, Chikugo City Hospital, Chikugo 833-0041, Japan
- Satoshi Itano
- Department of Gastroenterology, Kurume Central Hospital, Kurume 830-0001, Japan
- Kunitaka Fukuizumi
- Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka 810-8563, Japan
- Hiroshi Kawano
- Department of Gastroenterology, St. Mary’s Hospital, Kurume 830-8543, Japan
- Kazunori Noguchi
- Department of Gastroenterology, Omuta City Hospital, Omuta 836-0861, Japan
- Masatoshi Tanaka
- Department of Gastroenterology, Yokokura Hospital, Miyama 839-0215, Japan
- Taizo Yamaguchi
- Iwamoto Internal Medicine Clinic, Kitakyusyu 802-0832, Japan
- Ryoko Kuromatsu
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Atsushi Kawaguchi
- Center for Comprehensive Community Medicine Faculty of Medicine, Saga University, Saga 840-0027, Japan
- Hironori Koga
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- Takuji Torimura
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
- New FP Study Group
- Kurume Liver Cancer Study Group of Japan
- DOI
- https://doi.org/10.3390/cancers13040646
- Journal volume & issue
-
Vol. 13,
no. 4
p. 646
Abstract
BACKROUND: Not all patients with hepatocellular carcinoma (HCC) benefit from treatment with molecular targeted agents such as sorafenib. We investigated whether New-FP (fine-powder cisplatin and 5-fluorouracil), a hepatic arterial infusion chemotherapy regimen, is more favorable than sorafenib as an initial treatment for locally progressed HCC. METHODS: To avoid selection bias, we corrected the data from different facilities that did or did not perform New-FP therapy. In total, 1709 consecutive patients with HCC initially treated with New-FP or sorafenib; 1624 (New-FP, n = 644; sorafenib n = 980) were assessed. After propensity score matching (PSM), overall survival (OS) and prognostic factors were assessed (n = 344 each). Additionally, the patients were categorized into four groups: cohort-1 [(without macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort-2 (with MVI), cohort-3 (with EHS), and cohort-4 (with MVI and EHS) to clarify the efficacy of each treatment. RESULTS: New-FP prolonged OS than sorafenib after PSM (New-FP, 12 months; sorafenib, 7.9 months; p < 0.001). Sorafenib treatment, and severe MVI and EHS were poor prognostic factors. In the subgroup analyses, the OS was significantly longer the New-FP group in cohort-2. CONCLUSIONS: Local treatment using New-FP is a potentially superior initial treatment compared with sorafenib as a multidisciplinary treatment in locally progressed HCC without EHS.
Keywords